Neurobiology Underlying Fibromyalgia Symptoms

Article (PDF Available)inPain Research and Treatment 2012(2):585419 · January 2012with66 Reads
DOI: 10.1155/2012/585419 · Source: PubMed
Fibromyalgia is characterized by chronic widespread pain, clinical symptoms that include cognitive and sleep disturbances, and other abnormalities such as increased sensitivity to painful stimuli, increased sensitivity to multiple sensory modalities, and altered pain modulatory mechanisms. Here we relate experimental findings of fibromyalgia symptoms to anatomical and functional brain changes. Neuroimaging studies show augmented sensory processing in pain-related areas, which, together with gray matter decreases and neurochemical abnormalities in areas related to pain modulation, supports the psychophysical evidence of altered pain perception and inhibition. Gray matter decreases in areas related to emotional decision making and working memory suggest that cognitive disturbances could be related to brain alterations. Altered levels of neurotransmitters involved in sleep regulation link disordered sleep to neurochemical abnormalities. Thus, current evidence supports the view that at least some fibromyalgia symptoms are associated with brain dysfunctions or alterations, giving the long-held "it is all in your head" view of the disorder a new meaning.
Hindawi Publishing Corporation
Pain Research and Treatment
Volume 2012, Ar ticle ID 585419, 8 pages
Review A rticle
Neurobiology Underlying Fibromyalgia Symptoms
Marta Ceko,
1, 2
M. Catherine Bushnell,
1, 2, 3
and Richard H. Gracely
Alan Edwards Centre for Research on Pain, McGill University, 3640 University Street, Room M19, Montreal,
QC, Canada H2A 1C1
Department of Neurology & Neurosurgery, McGill University, 3640 University Street, Room M19, Montreal,
QC, Canada H2A 1C1
Department of Anesthesia, McGill University, 3640 University Street, Room M19, Montreal, QC, Canada H2A 1C1
Center for Neurosensory Disorders, University of North Carolina, C B No. 7280, 3330 Thurston Building, Chapel Hill,
NC 27599, USA
Correspondence should be addressed to Marta Ceko,
Received 27 April 2011; Accepted 23 August 2011
Academic Editor: Muhammad B. Yunus
Copyright © 2012 Marta Ceko et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided t he orig inal work is properly cited.
Fibromyalgia is characterized by chronic widespread pain, clinical sy mptoms that include cognitive and sleep disturbances, and
other abnormalities such as increased sensitivity to painful stimuli, increased sensitivity to multiple sensory modalities, and altered
pain modulatory mechanisms. Here we relate experimental findings of fibromyalgia symptoms to anatomical and functional
brain changes. Neuroimaging studies show augmented sensory processing in pain-related areas, which, together with gray matter
decreases and neurochemical abnormalities in areas related to pain modulation, supports the psychophysical evidence of altered
pain perception and inhibition. Gray matter decreases in areas related to emotional decision making and working memory suggest
that cognitive disturbances could be related to brain alterations. Altered levels of neurotransmitters involved in sleep regulation
link disordered sleep to neurochemical abnormalities. Thus, current evidence supports the view that at least some fibromyalgia
symptoms are associated with brain dysfunctions or alterations, giving the long-held “it is all in your head” view of the disorder a
new meaning.
1. Introduction
In order to examine the neurobiology underlying the
symptoms of fibromyalgia, we must first determine what
those symptoms are. Until recently, fibromyalgia (FM) was
diagnosed based on the ARC1990 criteria [1], which were
widespread pain in combination with tenderness at 11 or
more of 18 specific tender point sites. The provisional ACR
2010 FM diagnostic criteria [2],suggestedasanalternative
method of diagnosing FM, do not require the presence of
tenderness, but rather include a list of several other symp-
toms, including fatigue, unrefreshing sleep, and cognitive
symptoms, as well as a mix of some other s ymptoms that
could include headache, depression, and lower abdominal
pain/cramping. The hallmark symptom is still widespread
pain, and a diagnosis of fibromyalgia requires this symptom.
However, a patient must also have some of the other symp-
toms that are common among FM patients in order to reach
a composite score that would lead to a diagnosis of FM. In
addition to clinical symptoms that make up the diagnosis of
FM, experimental studies have identified a number of other
abnormalities in FM patients, including increased sensitivity
to multiple t ypes of painful stimuli, increased sensitivity to
other sensory modalities, and alterations in pain modulatory
mechanisms. Further, neuroimaging studies have found
functional, anatomical, and neurochemical dierences in the
brains of FM patients compared to healthy control subjects.
Most of the clinical symptoms associated with FM have
not been systematically studied in the experimental setting,
but there are a number of studies that have provided an
objective evaluation of the altered cognitive functioning
and sleep disturbances reported in FM patients. Thus, this
paper will focus on the experimental evidence related to FM
symptoms and connect these perceptual and cognitive signs
to abnormalities observed in the brains of FM patients.
2 Pain Research and Treatment
1.1.AlteredPainPerceptioninFMPatients.The hallmark
symptom of FM is widespread ongoing musculoskeletal
pain. In addition, FM patients have been distinguished from
other patients with widespread pain syndromes primarily by
the presence of tenderness that has been assessed clinically by
finding pain evoked by 4 kg manual pressure in at least 11 of
18 defined tender points. This tender point concept was not
based on an understanding of the underlying pathophysiol-
ogy, but rather on empirical observation. Thus, although the
ARC-90 diagnostic criteria provided an important uniform
tool for defining the FM syndrome, they did not validate the
tender point concept, due to the circular evidence on which
the criteria were based [3]. In fact, much evidence indicates
that tender points are just sites normally more sensitive to
pressure pain in all indiv iduals [47] and that FM patients
have an increased pressure sensitivity at non-tender-point
sitesaswell[8]. Accumulating evidence now shows that FM
patients have increased sensitiv ity to many types of painful
stimulation, including pressure at non-tender-point sites
[9], heat and cold pain [6, 1014], elec trical stimulation [6],
and intramuscular hypertonic saline injection [15]. Despite
the plethora of evidence for hypersensitivity to painful
stimuli, there is less evidence that FM patients are more
sensitive to innocuous somatosensory stimuli. Detection
thresholds for tactile and electrical stimuli are not altered
in FM [6, 12, 13], but Hollins et al. [16] found that FM
patients rated innocuous pressure as more intense than did
healthy controls, although the eects in the innocuous range
were weaker than in the noxious range. The evidence for
changes in cool or warm detection also is mixed, with most
investigators finding no dierences between FM and controls
for heat [6, 10]orcold[10, 12], whereas one study found
FM patients to have reduced heat detection thresholds [12],
and one study found patients to have reduced cold detection
thresholds [6]. Thus, it appears that the altered sensitivity
within the somatosensory system is more profound in the
noxious range than in the innocuous range.
1.2. Evidence for Generalized Hypersensitivity to Unpleasant
Stimuli. The hypersensitivity of FM patients to painful
stimuli has led some investigators to propose that fibromyal-
gia involves a hypervigilance to pain and pain-associated
information [1719]. However, there is now evidence that
the hypersensitivity to unpleasant stimuli extends beyond
the somatosensory system, which has led to the hypothesis
that there is a generalized hypervigilance for sensory stimuli
in FM [16, 20, 21]. A few studies have examined the
sensitivity of FM patients in modalities other than pain
and found perceptual amplification. FM patients have been
shown to have decreased tolerance of unpleasant noise [20]
and increased sensitivity to loud unpleasant auditory stimuli
that parallels their increased pressure pain sensitivity [22].
Similarly, FM patients perceive unpleasant olfactory stimuli
to be more intense and more unpleasant than do matched
controlsubjects[23]. On the other hand, when pleasant
odors were tested, FM patients and controls perceived the
odors as equally intense, consistent with another evidence
that the hypersensitivity across perceptual modalities may be
confined to stimuli in the unpleasant ra nge [24]. Neverthe-
less, for pleasant odors, although FM patients did not rate
them as more intense, they did evaluate the pleasant odors
as less pleasant than did control subjects. Further, a range of
auditory stimuli were rated as more intense by FM patients
than by controls, and auditory stimuli rated as mildly pleas-
ant by healthy subjects were rated as somewhat unpleasant
by FM patients [16]. The finding of hypersensitivity in mul-
tiple modalities of stimulation, particularly for unpleasant
stimuli, suggests that the evoked pain sensitivity of FM may
be related to an altered hedonic appreciation for sensory
stimuli, rather than to peripheral tissue abnormalities.
1.3. Other Phenomena Related to Altered Pain Percepti on.
Other types of evidence from experimental pain studies in
FM patients support the idea of a centrally mediated up-
regulation of nociceptive activit y in the CNS. A central
pathophysiological process that appears to be disturbed in
FM patients is the “w indup” of central nociceptive processing
of C-fibre input to the spinal cord, resulting in the perceptual
phenomenon of temporal summation of pain. Windup of
nociceptive activity is dependent on activation of the NMDA
receptor complex in the spinal cord by input from C-
nociceptors [25, 26]. Some FM patients show increased
temporal summation of pain and increased aftersensations at
the termination of noxious stimulation [27]. These enhanced
responses could be related to one or more of several possible
factors: (1) an ongoing peripheral source of input from C
nociceptors other than the applied stimulus; (2) sensitized
NMDA receptors on central nociceptive neurons; (3) abnor-
malities in descending modulation; (4) abnormal processing
at supraspinal levels. Evidence of increased sensitivity in mul-
tiple sensory modalities suggests that ongoing C-nociceptor
input cannot alone account for FM symptoms, indicating
that there probably also are either sensitized NMDA recep-
tors, abnormalities in modulatory systems in the brain, or
abnormal sensory processing at spinal or supraspinal levels.
Increased sensitivity has been demonstrated at the spinal
level in FM [11]. Staud et al. [28] showed that an NMDA
inhibitor reduced temporal summation in both healthy peo-
ple and FM patients, suggesting that NMDA receptors prob-
ably are not sensitized in FM. On the other hand, experimen-
tal evidence shows that there are abnormalities in pain mod-
ulatory systems in FM patients that could account for altered
temporal summation and other putative spinal eects.
1.4. Altered Pain Inhibition in FM Patients. For hundreds of
years, clinicians have known that pain inhibits pain, a phe-
nomenon termed “counterirritation. More recently, a phys-
iological basis of this phenomenon has been identified; the
application of noxious stimulation activates an endogenous
analgesic system involving supraspinal descending control
of dorsal horn nociceptive activity. This system is termed
“diuse noxious inhibitory control” or DNIC and its physio-
logical basis in the spinal cord has been studied extensively in
anesthetized animals [29, 30]. Nevertheless, w hen competing
noxious stimuli are presented in conscious humans, other
systems that modulate pain, such as distraction, also are
Pain Research and Treatment 3
probably in eect, so that care must be taken in inferring
that perceptual eects are due to DNIC. Accordingly, a
group of interested researchers has suggested that the term
conditioned pain modulation be used in humans studies
to avoid the mechanistic implication [31]. Studies that have
examined conditioned pain modulation in FM patients show
that conditioning stimuli that produce an analgesic response
to experimental pain stimuli in healthy control subjects
fail to have an eect on FM patients [13, 3234]. One of
these studies controlled for the eects of distraction and
habituation and found a similar lack of conditioned pain
modulation in FM patients [33], suggesting the possibility
that the DNIC system is in fact impaired in these individuals.
Alternatively, DNIC and other descending inhibitory systems
could be activated by the widespread pain of FM, and the
failure to demonstrate DNIC in FM could represent a ceiling
eect in which these activated systems cannot be fur ther
engaged by the experimental manipulations [8]. In addition,
distraction can have a powerful pain-inhibiting eect [35
39], and some researchers have suggested that FM patients
have altered attentional focusing, with a hypervigilance to
unpleasant stimuli (see discussion above).
2. Other Symptoms of FM
2.1. Altered Cognitive Function in FM Patients. In addition
to pain, many patients with fibromyalgia complain of prob-
lems with memory and concentration, often referred to
as “fibrofog” [4043]. This clinical symptom has received
a large amount of experimental study, and studies using
objective cognitive tests substantiate patients’ subjective
reports of cognitive dysfunctions, most commonly related
to speed of information processing, attention, and memory
[4356]. The most robust deficits in tests of memory and
attention have so far been observed in paradigms involv-
ing a prominent distraction from a competing source of
information, wherein FM patients are less capable than
healthy controls to retain new information when rehearsal
is prevented by a distraction [49, 50, 57]. Milder deficits have
been observed in memory free of distraction at encoding [43,
44, 48, 49, 51, 58, 59]. FM patients frequently display greater
impairments in the ability to actively retrie ve past episodic
events in the absence of a cue (free recall) than on recognition
tests, which serve to evaluate the retrieval of remembered
information and are more resistant to the eec ts of impaired
attention and concentration [43, 44, 48, 51]. It has thus been
proposed that memory impairments in FM are more highly
related to attentional factors that modulate the eciency of
memory functioning than to primary memory processes per
se [48, 60, 61]. Thus, the inability to manage distraction
seems to be a particular problem in fibromyalgia patients and
is reflected in patients’ reports of diculty concentrating and
dealing with complex, ra pidly changing environments [61]
and by memory tests showing performance decrements in
the presence of distraction. Impaired cognitive performance
is evident even after controlling for anxiety and depression
and the influence of medications that might aect cognitive
functioning [ 43, 50, 52, 58]. Another area of cognitive
functioning that has been shown to be abnormal in FM is
that of emotional decision making [ 62, 63]. A similar deficit
has been shown in chronic back pain patients, suggesting that
2.2. Sleep Disturbances in FM Patients. Many FM patients
complain of unrefreshed sleep. Several laboratory studies
using objective measures of sleep physiology such as EEG
substantiate these reports by showing disordered sleep
architecture in FM patients, including delayed onset to sleep,
altered sleep stage dynamics, a nd reduced slow w ave sleep
(deep sleep) and rapid-eye movement (REM) sleep [6568].
The intrusion of EEG frequencies characteristic of wakeful-
ness (alpha waves) in the deep non-REM sleep (delta waves)
seems to be a prominent feature of the nonrestorative sleep
of FM patients [65, 6971]. Further, patients with FM often
have fragmented sleep resulting from periodic intrusions
such as involuntary limb movements (restless legs), sleep
apnea, and arousal disturbances [68, 72
74]. Although FM
patients tend to report greater disturbances in sleep duration
and quality than shown in laboratory studies, and their
subjective reports correlate better with the severity of clinical
symptoms [75], objectively measured sleep disturbances
have been associated with pain and subjective daily sleepiness
in several studies [67, 68, 71, 73].
3. Brain Changes That Could
Underlie Symptoms
3.1. Neural Basis of Pain Amplification and Altered Pain
Modulation. Functional brain imaging studies support psy-
chophysical findings of increased pain perception in FM, in
that there is an aug mentation of sensory processing through-
out pain-related brain regions [9, 7681]. This is important,
since laboratory findings of increased sensitiv ity could be
interpreted as a reporting bias, rather than evidence of
increased activation in pain pathways. The functional imag-
ing studies have found that fibromyalgia patients show sig-
nificantly more activity in response to pressure and thermal
stimuli compared to controls in a number of brain regions.
Increased activations were observed not only in limbic
structures, but also in brain regions involved in sensory-
discriminative processing, such as primary and secondary
somatosensory cortices, which supports the view that neural
responses to aerent signals are amplified in fibromyalgia.
Although the increased pain-evoked brain activations
corroborate patients’ reports, the correlation between in-
creased brain activity and increased pain perception does
not explain how the aerent signal is amplified. As discussed
above, there is psychophysical evidence of dysfunctions in
pain modulation as well as pain perception. There is now
much evidence that the activation of descending control cir-
cuitry is involved in pain modulation and that this circuitry
includes parts of prefrontal, cingulate, and insular cortices
[23, 36, 37, 82, 83]. A number of anatomical imaging studies
in FM patients reveal decreased brain gray matter in these
regions [8490]. Although the cellular basis of decreased gray
matter in FM patients is not known, it is possible that due to
4 Pain Research and Treatment
neuronal loss, decreased dendritic arborisation, or changes in
glial activation, pain inhibitory systems do not work in FM
patients as well as in healthy individuals.
Consistent with the idea that pain modulatory systems
may be disturbed in fibromyalgia are data showing that some
FM patients have abnormalities in neurochemical systems
involved in pain control, including the forebrain opioid and
dopamine systems. A positron emission tomography (PET)
competitive binding study using the D2/D3 receptor antag-
onist [
C] raclopride showed that striatal dopamine is
released in response to painful muscle stimulation in healthy
subjects, but not in FM patients [15, 91], which might
partial ly explain the increased sensitivity of FM patients to
the painful muscle stimulation. For the opioid system, inves-
tigators using PET found that FM patients had decreased
binding potentials at rest for the exogenously administered
µ-opioid receptor agonist carfentanil in several brain areas,
including the ventral striatum, the anterior cingulate cortex,
and the amygdala [92]. These areas are implicated in pain
and its emotional modulation, and correspondingly, the
binding potentials showed a negative relationship with the
magnitude of aective pain scores relative to the sensory
scores. Although results of this study do not tell us whether
levels of endogenous opioids were increased or whether
receptor availability was decreased, the findings support the
notion that disturbances in the opioidergic system might be
related to the increased pain sensitivity in fibromyalgia. For
both dopamine and opioids, the ongoing widespread pain
of FM could lead to a tonic activation within these systems
and thus be a main factor in altering receptor availability
and associated responsiveness to externally applied painful
3.2. Ne ural Basis of Cognitive Symptoms. It is well known
that cognitive capabilities such as attention and memory
functions decline continuously across the adult lifespan
[93], which, together with findings of accelerated age-related
decline of brain gray matter observed in FM patients [84],
suggests that there may be a relationship between gray matter
reductions in FM and cognitive deficits in these patients.
Two recent studies have linked FM to impaired emotional
decision making [62, 63]. Anatomical imaging studies have
reported that FM patients have decreased gray matter in
the medial prefrontal and insular cortices [84, 85, 89], areas
implicated in emotional decision making [9499]. Together,
these data suggest a possible association between gray matter
loss and emotional decision making in FM. One study has
directly examined the relationship between performance on
working memory tasks and gray matter in FM patients
and found that an individual’s performance was positively
correlated with gray matter values in medial frontal and
anterior cingulate cortices, thereby providing direct evidence
for an association between altered working memory and
gray matter morphology in fibromyalgia [51]. Both of these
brain regions, together with lateral premotor cortex, lateral
prefrontal cortex, frontal poles, and posterior par ietal cortex,
are areas known to be related to working memory processes
[100105]. In terms of the neurochemical abnormalities
in FM discussed above, dopamine plays an important role
for cognitive functioning. Multiple lines of ev idence demon-
strate the importance of mesocortical and striatal dopamin-
ergic pathways in memory tasks, perceptual speed, and
response inhibition (see [106] for review). Thus, there is an
overlap between tasks in which fibromyalgia patients per-
form poorly and tasks that are related to dopamine func tion-
ing, suggesting that a dysfunctional dopamine system could
contribute to the cognitive symptoms of fibromyalgia.
3.3. Neural Basis of Sleep Disturbances. While many studies
have used EEG and related methods to show various aspects
of disordered sleep physiology in FM patients, little is known
about the neurobiology underlying these disturbances. Sev-
eral neurotransmitters have been proposed to influence
CNS hypersensitivit y associated with sleep alterations. For
example, inhibition of the CNS serotonin synthesis has been
linked to insomnia and increased pain sensitivity [107].
Accordingly, in FM there is evidence for low serum and
cerebrospinal fluid serotonin levels [108, 109]. Injecting
amounts of substance P into the CNS of rats has been shown
to reduce sleep eciency, increasing latency to onset to sleep
and provoking awakenings from sleep [110], and there is
evidence for elevated cerebrospinal fluid levels of substance
P in FM patients [111, 112].
3.4. What Do the Psychophysical, Cognitive, and Neuroimaging
Studies Tell Us about the Neurobiology Underlying FM
Symptoms? The wealth of experimental evidence showing
that FM patients are hypersensitive to painful stimuli, as
well as unpleasant stimuli from other sensory modalities,
in conjunction with func tional brain imaging data showing
increased stimulus-evoked activation throughout nocicep-
tive pathways, shows that the defining symptom of FM—
increased pain—is in fact real and not just a response bias
of the patients. The finding that perception is increased in
multiple modalities speaks against the hypothesis that FM
pain is due to an upregulation of peripheral nociceptive
processes. Further, psychophysical evidence that descending
modulatory systems are altered in FM patients supports the
opposing idea that FM symptoms are at least in part caused
by alterations in CNS processing of the pain signal, including
a dysregulation of pain modulatory systems. Nevertheless,
the apparent dysregulation within these systems could be
caused and/or perpetuated by a tonic activation related to the
presence of ongoing widespread pain, so that the systems are
saturated and cannot regulate further in response to external
Since similar descending control systems, including
attentional and emotional regulatory circuitry, aect mul-
tiple sensory modalities [113119], a dysfunction (or satu-
ration) in these systems could lead to the hypersensitivity
in multiple sensory modalities. FM patients show reduced
habituation to nonpainful tactile stimuli and increased
cortical response to intense auditory stimuli, both of which
have been linked to deficient inhibition of incoming sensory
stimuli [120, 121]. Also in support of the idea of a central
dysregulation or saturation of pain modulation are changes
Pain Research and Treatment 5
in the opioid and dopamine neurotransmitter systems, both
known to be involved in hedonic regulation [122].
Finally, the findings that FM patients not only perceive
themselves to have altered memory and concentration
(“fibrofog”), but also in fact perform poorly on multiple
cognitive tests, even when depression is excluded as a
contributing factor, suggest that there are alterations in
brain function. The anatomical brain imaging studies that
show reductions in gray matter in frontal regions important
for cognitive function further indicate that this common
symptom of FM is based on altered brain function. Together,
the experimental evidence provides strong support for the
idea that FM symptoms are related to dysfunctions in the
central ner vous system. The cause of these changes cannot be
deduced from the available evidence, as it is correlational in
nature. D id long-term ongoing pain cause the changes or did
the changes cause the pain? Without a relevant animal model
or long-term longitudinal studies, we cannot answer these
questions. Nevertheless, we can at least say that fibromyalgia
is real and that it is associated with multiple changes in the
[1] F. Wolfe, H. A. Smythe, M. B. Yunus et al., “The American
College of Rheumatology 1990. Criteria for the classification
of fibromyalgia. Report of the Multicenter Criteria Commit-
tee, Arthritis and Rheumatism, vol. 33, no. 2, pp. 160–172,
[2] F. Wolfe, D. J. Clauw, M.-A. Fitzcharles et al., “Fibromyalgia
criteria and severity scales for clinical and epidemiological
studies: a modification of the ACR preliminary diagnostic
criteria for fibromyalgia, Journal of Rheumatology, vol. 38,
no. 6, pp. 1113–1122, 2011.
[3] M. L. Cohen and J. L. Quintner, “Fibromyalgia syndrome, a
problem of tautology, Lancet, vol. 342, no. 8876, pp. 906–
909, 1993.
[4] G. Granges and G. Littlejohn, “Pressure pain threshold in
pain-free subjects, in patients with chronic regional pain
syndromes, and in patients with fibromyalgia syndrome,
Arthritis and Rheumatism, vol. 36, no. 5, pp. 642–646, 1993.
[5] S. Lautenbacher and J. C. Krieg, “Pain perception in
psychiatric disorders: a review of the literature, Journal of
Psychiatric Research, vol. 28, no. 2, pp. 109–122, 1994.
[6] S. Lautenbacher, G. B. Rollman, and G. A. McCain, “Multi-
method assessment of experimental and clinical pain in pa-
tients with fibromyalgia, Pain, vol. 59, no. 1, pp. 45–53, 1994.
[7] E. Tunks, J. Crook, G. Norman, and S. Kalaher, “Tender
points in fibromyalgia, Pain, vol. 34, no. 1, pp. 11–19, 1988.
[8] R. H. Gracely, M. A. B. Grant, and T. Giesecke, “Evoked pain
measures in fibromyalgia, Best Practice and Research, vol. 17,
no. 4, pp. 593–609, 2003.
[9] R. H. Gracely, F. Petzke, J. M. Wolf, and D. J. Clauw, “Func-
tional magnetic resonance imaging evidence of augmented
pain processing in fibromyalgia, Arthritis and Rheumatism,
vol. 46, no. 5, pp. 1333–1343, 2002.
[10] B. Berglund, E. L. Harju, E. Kosek, and U. Lindblom, “Quan-
titative and qualitative perceptual analysis of cold dyses-
thesia and hyperalgesia in fibromyalgia, Pain, vol. 96, no.
1-2, pp. 177–187, 2002.
[11] J. A. Desmeules, C. Cedraschi, E. Rapiti et al., “Neurophys-
iologic evidence for a central sensitization in patients with
fibromyalgia, Arthritis and Rheumatism,vol.48,no.5,pp.
1420–1429, 2003.
[12] E. Kosek, J. Ekholm, and P. Hansson, “Sensory dysfunction
in fibromyalgia patients with implications for pathogenic
mechanisms, Pain, vol. 68, no. 2-3, pp. 375–383, 1996.
[13] S. Lautenbacher and G. B. Rollman, “Possible deficiencies of
pain modulation in fibromyalgia, Clinical Journal of Pain,
vol. 13, no. 3, pp. 189–196, 1997.
[14] F. Petzke, D. J. Clauw, K. Ambrose, A. Khine, and R. H.
Gracely, “Increased pain sensitivity in fibromyalgia: eects of
stimulus type and mode of presentation, Pain, vol. 105, no.
3, pp. 403–413, 2003.
[15] P. B. Wood, P. Schweinhardt, E. Jaeger et al., “Fibromyalgia
patients show an abnormal dopamine response to pain,
European Journal of Neuroscience, vol. 25, no. 12, pp. 3576–
3582, 2007.
[16] M. Hollins, D. Harper, S. Gallagher et al., “Perceived intensity
and unpleasantness of cutaneous and auditory stimuli: an
evaluation of the generalized hypervigilance hypothesis,
Pain, vol. 141, no. 3, pp. 215–221, 2009.
[17] G. J. G. Asmundson, J. L. Kuperos, and G. R. Norton, “Do
patients with chronic pain selectively attend to pain-related
information? Preliminary evidence for the mediating role of
fear, Pain, vol. 72, no. 1-2, pp. 27–32, 1997.
[18] E. Keogh, D. Ellery, C. Hunt, and I. Hannent, “Selective
attentional bias for pain-related stimuli amongst pain fearful
individuals, Pain, vol. 91, no. 1-2, pp. 91–100, 2001.
[19] G. Crombez, C. Eccleston, A. V. Den Broeck, L. Goubert, and
B. Van Houdenhove, “Hypervigilance to pain in fibromyal-
gia: the mediating role of pain intensity and catast rophic
thinking about pain, Clinical Journal of Pain, vol. 20, no. 2,
pp. 98–102, 2004.
[20] A. J. McDermid, G. B. Rollman, and G. A. McCain, “Gener-
alized hypervigilance in fibromyalgia: evidence of perceptual
amplification, Pain, vol. 66, no. 2-3, pp. 133–144, 1996.
[21] J. L. Gonz
alez, F. Mercado, P. Barjola et al., Generalized
hypervigilance in fibromyalgia patients: an experimental
analysis with the emotional Stroop paradigm, Journal of Psy-
chosomatic Research, vol. 69, no. 3, pp. 279–287, 2010.
[22] M. E. Geisser, J. M. Glass, L. D. Rajcevska et al., A
psychophysical study of auditory and pressure sensitivity in
patients with fibromyalgia and healthy controls, Journal of
Pain, vol. 9, no. 5, pp. 417–422, 2008.
[23] P. Schweinhardt, K. M. Sauro, and M. C. Bushnell,
“Fibromyalgia: a disorder of the brain?” Neuroscientist, vol.
14, no. 5, pp. 415–421, 2008.
[24] E. J. Bartley, J. L. Rhudy, and A. E. Williams, “Experimental
assessment of aective processing in fibromyalgia, Journal of
Pain, vol. 10, no. 11, pp. 1151–1160, 2009.
[25] A. H. Dickenson, A cure for wind up: NMDA receptor
antagonists as potential analgesics, Trends in Pharmacolog-
ical Sciences, vol. 11, no. 8, pp. 307–309, 1990.
[26] C. J. Woolf and S. W. N. Thompson, The induction and
maintenance of central sensitization is dependent on N-
methyl-D-aspartic acid receptor activation; implications for
the treatment of post-injury pain hypersensitivity states,
Pain, vol. 44, no. 3, pp. 293–299, 1991.
[27] R. Staud, C. J. Vierck, R. L. Cannon, A. P. Mauderli, and D.
D. Price, Abnormal sensitization and temporal summation
of second pain (wind-up) in patients with fibromyalgia
syndrome, Pain, vol. 91, no. 1-2, pp. 165–175, 2001.
6 Pain Research and Treatment
[28] R. Staud, C. J. Vierck, M. E. Robinson, and D. D. Price,
“Eects of the N-methyl-D-aspartate receptor antagonist
dextromethorphan on temporal summation of pain are
similar in fibromyalgia patients and normal control subjects,
Journal of Pain, vol. 6, no. 5, pp. 323–332, 2005.
[29] D. Le Bars, A. H. Dickenson, and J. M. Besson, “Diuse
noxious inhibitory controls (DNIC). I. Eects on dorsal horn
convergent neurones in the rat, Pain, vol. 6, no. 3, pp. 283–
304, 1979.
[30] D. Le Bars, A. H. Dickenson, and J. M. Besson, “Diuse
noxious inhibitory controls (DNIC). II. Lack of eect on
non-convergent neurones, supraspinal involvement and the-
oretical implications, Pain, vol. 6, no. 3, pp. 305–327, 1979.
[31] D. Yarnitsky, L. Arendt-Nielsen, D. Bouhassira et al., “Recom-
mendations on terminology and practice of psychophysical
DNIC testing, European Journal of Pain , vol. 14, no. 4, p. 339,
[32] E. Kosek and P. Hansson, “Modulatory influence on
somatosensory perception from vibration and heterotopic
noxious conditioning stimulation (HNCS) in fibromyalgia
patients and healthy subjects, Pain, vol. 70, no. 1, pp. 41–51,
[33] N. Julien, P. Goaux, P. Arsenault, and S. Marchand,
“Widespread pain in fibromyalgia is related to a deficit of
endogenous pain inhibition, Pain, vol. 114, no. 1-2, pp. 295–
302, 2005.
[34] E. Normand, S. Potvin, I. Gaumond, G. Cloutier, J.-F. Corbin,
and S. Marchand, “Pain inhibition is deficient in chronic
widespread pain but normal in major depressive disorder,
Journal of Clinical Psychiatry, vol. 72, no. 2, pp. 219–224,
[35] I. Tracey, A. Ploghaus, J. S. Gati e t al., “Imaging attentional
modulation of pain in the periaqueductal gray in humans,
Journal of Neuroscience, vol. 22, no. 7, pp. 2748–2752, 2002.
[36] K. Wiech, M. Ploner, and I. Tracey, “Neurocognitive aspects
of pain perception, Trends in Cognitive Sciences, vol. 12, no.
8, pp. 306–313, 2008.
[37] C. Villemure and M. C. Bushnell, “Mood influences su-
praspinal pain processing separately from attention, Journal
of Neuroscience, vol. 29, no. 3, pp. 705–715, 2009.
[38] C. Villemure and P. Schweinhardt, “Supraspinal pain pro-
cessing: distinct roles of emotion and attention, Neuroscien-
tist, vol. 16, no. 3, pp. 276–284, 2010.
[39] C. Villemure, B. M. Slotnick, and M. C. Bushnell, “Eects of
odors on pain perception: deciphering the roles of emotion
and attention, Pain, vol. 106, no. 1-2, pp. 101–108, 2003.
[40] R. M. Bennett, J. Jones, D. C. Turk, I. J. Russell, and L.
Matallana, An internet sur vey of 2,596 people with fibro-
myalgia, BMC Musculoskeletal Disorders, vol. 8, article 27,
[41] R. S. Katz, A. R. Heard, M. Mills, and F. Leavitt, “The
prevalence and clinical impact of reported cognitive dicul-
ties (Fibrofog) in patients with rheumatic disease with and
without fibromyalgia, Journal of Clinical Rheumatology, vol.
10, no. 2, pp. 53–58, 2004.
[42] F. Leavitt, R. S. Katz, M. Mills, and A. R. Heard, “Cognitive
and dissociative manifestations in fibromyalgia, Journal of
Clinical Rheumatology, vol. 8, no. 2, pp. 77–84, 2002.
[43] J. M. Glass, D. C. Park, M. Minear, and L. J. Croord, “Mem-
ory beliefs and function in fibromyalgia patients, Journal
of Psychosomatic Research, vol. 58, no. 3, pp. 263–269, 2005.
[44] N. I. Landrø, T. C. Stiles, and H. Sletvold, “Memory func-
tioning in patients with primary fibromyalgia and major
depression and healthy controls, Journal of Psychosomatic
Research, vol. 42, no. 3, pp. 297–306, 1997.
processing in primary fibromyalgia, major depression and
healthy controls, Journal of Rheumatology,vol.22,no.1,pp.
137–142, 1995.
[46] J. A. Suhr, “Neuropsychological impairment in fibromyalgia:
relation to depression, fatigue, and pain, Journal of Psycho-
somatic Research, vol. 55, no. 4, pp. 321–329, 2003.
[47] K. A. Cote and H. Moldofsky, “Sleep, daytime symptoms, and
cognitive performance in patients with fibromyalgia, Journal
of Rheumatology, vol. 24, no. 10, pp. 2014–2023, 1997.
[48] G. M. Grace, W. R. Nielson, M. Hopkins, and M. A.
Berg, “Concentration and memory deficits in patients with
Fibromyalgia Syndrome, Journal of Clinical and Experimen-
tal Neuropsychology, vol. 21, no. 4, pp. 477–487, 1999.
[49] F. Leavitt and R. S. Katz, “Distraction as a key determinant of
impaired memory in patients with fibromyalgia, Journal of
Rheumatology, vol. 33, no. 1, pp. 127–132, 2006.
[50] B.D.Dick,M.J.Verrier,K.T.Harker,andS.Rashiq,“Disrup-
tion of cognitive function in Fibromyalgia Syndrome, Pain,
vol. 139, no. 3, pp. 610–616, 2008.
[51] R. Luerding, T. Weigand, U. Bogdahn, and T. Schmidt-
Wilcke, “Working memory per formance is correlated with
local brain morphology in the medial frontal and anterior
cingulate cortex in fibromyalgia patients: structural corre-
lates of pain-cognition interaction, Brain, vol. 131, no. 12,
pp. 3222–3231, 2008.
[52] B. Dick, C. Eccleston, and G. Crombez, Attentional func-
tioning in fibromyalgia, rheumatoid arthritis, and muscu-
loskeletal pain patients, Arthritis Care and Research, vol. 47,
no. 6, pp. 639–644, 2002.
[53] F. Leavitt and R. S. Katz, “Speed of mental operations in
fibromyalgia a selective naming speed deficit, Journal of
Clinical Rheumatology, vol. 14, no. 4, pp. 214–218, 2008.
[54] A. Correa, E. Mir
o, M. P. Mart
ınez, A. I. S
anchez, and J.
nez, Temporal preparation and inhibitory deficit in
fibromyalgia syndrome, Brain and Cognition, vol. 75, pp.
211–216, 2011.
[55] E. Miro, J. Lupianez, E. Hita, M. P. Martinez, A. I. Sanchez,
and G. Buela-Casal, Attentional deficits in fibromyalgia
and its relationships with pain, emotional distress and sleep
dysfunction complaints, Psychology and Health, vol. 26, no.
6, pp. 765–780, 2011.
[56] S. H. Kim, S. H. Kim, S. K. Kim, E. J. Nam, S. W. Han, and S. J.
Lee, “Spatial versus verbal memor y impairments in patients
with fibromyalgia, Rheumatology International. In press.
[57] D. Mungu
ıa-Izquierdo and A. Legaz-Arrese, Assessment of
the eects of aquatic therapy on global sy mptomatology in
patients with fibromyalgia syndrome: a randomized con-
trolled trial, Archives of Physical Medicine and Rehabilitation,
vol. 89, no. 12, pp. 2250–2257, 2008.
[58] D. C. Park, J. M. Glass, M. Minear, and L. J. Croord,
“Cognitive function in fibromyalgia patients, Arthritis and
Rheumatism, vol. 44, no. 9, pp. 2125–2133, 2001.
[59] F. Leavitt and R. S. Katz, “Normalizing memory recall in
fibromyalgia with rehearsal: a distraction-counteracting ef-
fect, Arthrit is Care and Research, vol. 61, no. 6, pp. 740–744,
[60] T. Schmidt-Wilcke, P. Wood, and R. L
urding, “Cognitive
impairment in patients suering from fibromyalgia: an
underestimated problem, Schmerz, vol. 24, no. 1, pp. 46–53,
Pain Research and Treatment 7
[61] J. M. Glass, “Review of cognitive dysfunction in fibromyalgia:
a convergence on working memory and attentional control
impairments, Rheumatic Disease Clinics of North America,
vol. 35, no. 2, pp. 299–311, 2009.
[62] A. Verdejo-Garc
ıa, F. L
opez-Torrecillas, E. P. Calandre, A.
ıguez, and A. Bechara, “Executive f unction and
decision-making in women with fibromyalgia, Archives of
Clinical Neuropsycholog y, vol. 24, no. 1, pp. 113–122, 2009.
[63] C. Walteros, J. P. S
anchez-Navarro, M. A. Mu
noz, J. M.
ınez-Selva, D. Chialvo, and P. Montoya, Altered asso-
ciative learning and emotional decision making in fibromyal-
gia, Journal of Psychosomatic Research, vol. 70, pp. 294–301,
[64] A. V. Apkarian, Y. Sosa, B. R. Krauss et al., “Chronic pain pa-
tients are impaired on an emotional decision-making task,
Pain, vol. 108, no. 1, pp. 129–136, 2004.
[65] J. A. Horne and B. S. Shackell, Alpha-like EEG activity in
non-REM sleep and the fibromyalgia (fibrositis) syndrome,
Electroencephalography and Clinical Neurophysiology, vol. 79,
no. 4, pp. 271–276, 1991.
[66] A. M. Drewes, K. D. Nielsen, S. J. Taagholt, L. Bjerregard, L.
Svendsen, and J. Gade, “Sleep intensity in fibromyalgia: focus
on the microstructure of the sleep process, British Journal of
Rheumatology, vol. 34, no. 7, pp. 629–635, 1995.
[67] J. W . Burns, L. J. Croord, and R. D. Chervin, “Sleep stage
dynamics in fibromyalgia patients and controls, Sleep Med-
icine, vol. 9, no. 6, pp. 689–696, 2008.
[68] P. Sarzi-Puttini, M. Rizzi, A. Andreoli et al., “Hypersomno-
lence in fibromyalgia syndrome, Clinical and Experimental
Rheumatology, vol. 20, no. 1, pp. 69–72, 2002.
[69] H. Moldofsky and F. A. Lue, “The relationship of alpha and
delta EEG frequencies to pain and mood in fibrositis pa-
tients treated with chlorpromazine and L-tryptophan, Elec-
troencephalography and Clinical Neurophysiology, vol. 50, no.
1-2, pp. 71–80, 1980.
[70] M. L. Perlis, D. E. Giles, R. R. Bootzin et al., Alpha sleep
and information processing, perception of sleep, pain, and
arousability in fibromyalgia, International Journal of Neuro-
science, vol. 89, no. 3-4, pp. 265–280, 1997.
[71] S. Roizenblatt, H. Moldofsky, A. A. Benedito-Silva, and S.
Tufik, Alpha sleep characteristics in fibromyalgia, Arthritis
and Rheumatism, vol. 44, no. 1, pp. 222–230, 2001.
[72] P. Jennum, A. M. Drewes, A. Andreasen, and K. D. Nielsen,
“Sleep and other symptoms in primary fibromyalgia and in
healthy controls, Journal of Rheumatology, vol. 20, no. 10, pp.
1756–1759, 1993.
[73] M. Rizzi, P. Sarzi-Puttini, F. Atzeni et al., “Cyclic alternating
pattern: a new marker of sleep alteration in patients with
fibromyalgia?” Journal of Rheumatology,vol.31,no.6,pp.
1193–1199, 2004.
[74] M. Viola-Saltzman, N. F. Watson, A. Bogart, J. Goldberg,
and D. Buchwald, “High prevalence of restless legs syn-
drome among patients with fibromyalgia: a controlled cross-
sectional study, Journal of Clinical Sleep Medicine, vol. 6, no.
5, pp. 423–427, 2010.
[75] A. Okifuji and B. D. Hare, “Nightly analyses of subjective
and objective (actigraphy) measures of sleep in fibromyalgia
syndrome: what accounts for the discrepancy?” The Clinical
Journal of Pain, vol. 27, pp. 289–296, 2010.
[76] D.B.Cook,G.Lange,D.S.Ciccone,W.C.Liu,J.Steener,
and B. H. Natelson, “Functional imaging of pain in patients
with primary fibromyalgia, Journal of Rheumatology, vol. 31,
no. 2, pp. 364–378, 2004.
[77] M. Burgmer, E. Pogatzki-Zahn, M. Gaubitz, E. Wessoleck, G.
Heuft, and B. Pfleiderer, Altered brain activity during pain
processing in fibromyalgia, NeuroImage,vol.44,no.2,pp.
502–508, 2009.
[78] M. Diers, M. T. Schley, M. Rance et al., “Dierential central
pain processing following repetitive intramuscular proton/
prostaglandin E
injections in female fibromyalgia patients
and healthy controls, European Journal of Pain, vol. 15, no.
7, pp. 716–723, 2011.
[79] M. Diers, C. Koeppe, P. Yilmaz e t al., “Pain ratings and
somatosensory evoked responses to repetitive intramuscular
and intracutaneous stimulation in fibromyalgia syndrome,
Journal of Clinical Neurophysiology, vol. 25, no. 3, pp. 153–
160, 2008.
[80] J. Pujol, M. L
a, H. Ortiz et al., “Mapping brain
response to pain in fibromyalgia patients using temporal
analysis of fMRI, PLoS ONE, vol. 4, no. 4, Article ID e5224,
[81] R. Staud, J. G. Craggs, W. M. Perlstein, M. E. Robinson, and
D. D. Price, “Brain activity associated with slow temporal
summation of C-fiber evoked pain in fibromyalgia patients
and healthy controls, European Journal of Pain, vol. 12, no.
8, pp. 1078–1089, 2008.
[82] P. Schweinhardt and M. C. Bushnell, “Pain imaging in health
and disease—how far have we come?” Journal of Clinical
Investigation, vol. 120, no. 11, pp. 3788–3797, 2010.
[83] T. D. Wager, J. K. Rilling, E. E. Smith et al., “Placebo-induced
changes in FMRI in the anticipation and experience of pain,
Science, vol. 303, no. 5661, pp. 1162–1167, 2004.
[84] A. Kuchinad, P. Schweinhardt, D. A. Seminowicz, P. B. Wood,
B. A. Chizh, and M. C. Bushnell, Accelerated brain gray
matter loss in fibromyalgia patients: premature aging of the
brain?” Journal of Neuroscience, vol. 27, no. 15, pp. 4004–
4007, 2007.
[85] M. Burgmer, M. Gaubitz, C. Konrad et al., “Decreased gray
matter volumes in the cingulo-frontal cortex and the amyg-
dala in patients with fibromyalgia, Psychosomatic Medicine,
vol. 71, no. 5, pp. 566–573, 2009.
“Changes in gray matter density in fibromyalgia: correlation
with dopamine metabolism, JournalofPain, vol. 10, no. 6,
pp. 609–618, 2009.
[87] J. Lutz, L. J
ager, D. De Quervain et al., “White and gray matter
abnormalities in the brain of patients with fi bromyalgia: a
diusion-tensor and volumetric imaging study, Arthritis and
Rheumatism, vol. 58, no. 12, pp. 3960–3969, 2008.
[88] T. Schmidt-Wilcke, R. Luerding, T. Weigand et al., “Stri-
atal grey matter increase in patients suering from fibro-
myalgia—A voxel-based morphometry study, Pain, vol. 132,
no. 1, pp. S109–S116, 2007.
[89] M. E. Robinson, J. G. Craggs, D. D. Price, W. M. Perlstein, and
R. Staud, “Gray matter volumes of pain-related brain areas
are decreased in fibromyalgia syndrome, Journal of Pain, vol.
12, no. 4, pp. 436–443, 2011.
[90] B.K.Puri,M.Agour,K.D.R.Gunatilake,K.A.C.Fernando,
A. I. Gurusinghe, and I. H. Treasaden, “Reduction in left
supplementary motor area grey matter in adult female fibro-
myalgia suerers with marked fatigue and without aective
disorder: a pilot controlled 3-T magnetic resonance imaging
voxel-based morphometry study, Journal of International
Medical Research, vol. 38, no. 4, pp. 1468–1472, 2010.
[91] D. J. Scott, M. M. Heitzeg, R. A. Koeppe, C. S. Stohler, and J.
K. Zubieta, “Variations in the human pain stress experience
mediated by ventral and dorsal basal ganglia dopamine
8 Pain Research and Treatment
activity, Journal of Neuroscience, vol. 26, no. 42, pp. 10789–
10795, 2006.
[92] R. E. Harris, D. J. Clauw, D. J. Scott, S. A. McLean, R. H.
Gracely, and J. K. Zubieta, “Decreased central mu-opioid
receptor availability in fibromyalgia, Journal of Neuroscience,
vol. 27, no. 37, pp. 10000–10006, 2007.
[93] D. C. Park and A. H. Gutchess, Aging, cognition, and cul-
ture: a neuroscientific perspective, Neuroscience and Biobe-
havioral Reviews, vol. 26, no. 7, pp. 859–867, 2002.
[94] A. Bechara, D. Tranel, and H. Damasio, “Characterization
of the decision-making deficit of patients with ventromedial
prefrontal cortex lesions, Brain, vol. 123, no. 11, pp. 2189–
2202, 2000.
[95] L. Clark, A. Bechara, H. Damasio, M. R. F. Aitken, B. J.
Sahakian, and T. W. Robbins, “Dierential eects of insular
and ventromedial prefrontal cortex lesions on risky decision-
making, Brain, vol. 131, no. 5, pp. 1311–1322, 2008.
[96] G. Northo, S. Grimm, H. Boeker et al., Aective judgment
and beneficial decision making: ventromedial prefrontal
activity correlates with performance in the Iowa Gambling
Tas k ,” Human Brain Mapping, vol. 27, no. 7, pp. 572–587,
[97] H. Fukui, T. Murai, H. Fukuyama, T. Hayashi, and T.
Hanakawa, “Functional activity related to risk anticipation
during performance of the Iowa gambling task, NeuroImage,
vol. 24, no. 1, pp. 253–259, 2005.
[98] R. Bar-On, D. Tranel, N. L. Denburg, and A. Bechara,
“Exploring the neurological substrate of emotional and social
intelligence, Brain, vol. 126, no. 8, pp. 1790–1800, 2003.
[99] M. P. Paulus, C. Rogalsky, A. Simmons, J. S. Feinstein, and
M. B. Stein, “Increased activation in the right insula during
risk-taking decision making is related to harm avoidance
and neuroticism, NeuroImage, vol. 19, no. 4, pp. 1439–1448,
[100] A. M. Owen, K. M. McMillan, A. R. Laird, and E. Bullmore,
“N-back working memory paradigm: a meta-analysis of
normative functional neuroimaging studies, Human Brain
Mapping, vol. 25, no. 1, pp. 46–59, 2005.
[101] N. G. M
uller and R. T. Knight, The functional neu-
roanatomy of working memory: contributions of human
brain lesion studies, Neuroscience, vol. 139, no. 1, pp. 51–58,
[102] A. S. Champod and M. Petrides, “Dissociable roles of the pos-
terior parietal and the prefrontal cortex in manipulation and
monitoring processes, Proceedings of the National Academy
of Sciences of the United States of America, vol. 104, no. 37,
pp. 14837–14842, 2007.
[103] J. D. Ragland, B. I. Turetsky, R. C. Gur et al., “Working mem-
ory for complex figures: an fMRI comparison of letter and
fractal n-back tasks, Neuropsychology, vol. 16, no. 3, pp. 370–
379, 2002.
[104] D. J. Veltman, S. A. R. B. Rombouts, and R. J. Dolan, “Main-
tenance versus manipulation in verbal working memory
revisited: an fMRI study, NeuroImage, vol. 18, no. 2, pp. 247–
256, 2003.
[105] J. D. Cohen, W. M. Perlstein, T. S. Braver et al., “Temporal
dynamics of brain activation during a working memory task,
Nature, vol. 386, no. 6625, pp. 604–611, 1997.
[106] L. B
ackman, L. Nyberg, U. Lindenberger, S. C. Li, and L.
Farde, “The correlative triad among aging, dopamine, and
cognition: current status and future prospects, Neuroscience
and Biobehavioral Reviews , vol. 30, no. 6, pp. 791–807, 2006.
[107] H. Moldofsky, “Rheumatic pain modulation syndrome: the
interrelationships between sleep, central nervous system
serotonin, and pain,
Advances in neurolog y, vol. 33, pp. 51–
57, 1982.
[108] I. J. Russell, J. E. Michalek, G. A. Vipraio, E. M. Fletcher, M.
A. Javors, and C. A. Bowden, “Platelet 3H-imipramine uptake
receptor density and serum serotonin levels in patients with
fibromyalgia/fibrositis syndrome, Journal of Rheumatology,
vol. 19, no. 1, pp. 104–109, 1992.
[109] I. J. Russell, H. Vaeroy, M. Javors, and F. Nyberg, “Cere-
brospinal fluid biogenic amine metabolites in fibromyal-
gia/fibrositis syndrome and rheumatoid arthr itis, Arthritis
and Rheumatism, vol. 35, no. 5, pp. 550–556, 1992.
[110] M. L. Andersen, D. C. Nascimento, R. B. MacHado, S.
Roizenblatt, H. Moldofsky, and S. Tufik, “Sleep disturbance
induced by substance P in mice, Behavioural Brain Research,
vol. 167, no. 2, pp. 212–218, 2006.
[111] I. J. Russell, M. D. Orr, B. Littman et al., “Elevated cere-
brospinal fluid levels of substance P in patients with the
fibromyalgia syndrome, Arthritis and Rheumatism, vol. 37,
no. 11, pp. 1593–1601, 1994.
[112] H. Vaeroy, R. Helle, O. Forre, E. Kass, and L. Terenius,
“Elevated CSF levels of substance P and high incidence of
Raynaud phenomenon in patients with fibromalgia: new
features for diagnosis, Pain, vol. 32, no. 1, pp. 21–26, 1988.
[113] A. R. Mayer, F. M. Hanlon, A. R. Franco et al., “The neural
networks underlying auditory sensory gating, NeuroImage,
vol. 44, no. 1, pp. 182–189, 2009.
[114] M. I. Posner and J. Driver, “T he neurobiology of selective
attention, Current Opinion in Neurobiology,vol.2,no.2,pp.
165–169, 1992.
[115] S. McMains and S. Kastner, “Interactions of top-down and
bottom-up mechanisms in human visual cortex, Journal of
Neuroscience, vol. 31, no. 2, pp. 587–597, 2011.
[116] F. Grabenhorst and E. T. Rolls, Attentional modulation of
aective versus sensory processing: functional connectivity
and a top-down biased activation theory of selective atten-
tion, Journal of Neurophysiology, vol. 104, no. 3, pp. 1649–
1660, 2010.
[117] W. R. Staines, S. J. Graham, S. E. Black, and W. E. McIlroy,
“Task-relevant modulation of contralateral and ipsilateral
primary somatosensory cortex and the role of a prefrontal-
cortical sensory gating system, NeuroImage,vol.15,no.1,
pp. 190–199, 2002.
[118] T. Bardouille, T. W. Picton, and B. Ross, Attention modu-
lates beta oscillations during prolonged tactile stimulation,
European Journal of Neuroscience, vol. 31, no. 4, pp. 761–769,
[119] P. Montoya and C. Sitges, Aective modulation of
somatosensory-evoked potentials elicited by tactile stimula-
tion, Brain Research, vol. 1068, no. 1, pp. 205–212, 2006.
[120] P. Montoya, C. Sitges, M. Garc
ıa-Herrera et al., “Reduced
brain habituation to somatosensory stimulation in patients
with fibromyalgia, Arthritis and Rheumatism, vol. 54, no. 6,
pp. 1995–2003, 2006.
[121] M. T. Carrillo-de-la-Pe
erez, and C.
omez-Perretta, “Intensity dependence of auditory-evoked
cortical potentials in fibromyalgia patients: a test of the
generalized hypervigilance hypothesis, Journal of Pain, vol.
7, no. 7, pp. 480–487, 2006.
[122] G. F. Koob, “Neural mechanisms of drug reinforcement,
Annals of the New York Academy of Sciences, vol. 654, pp. 171–
191, 1992.
    • "Abnormalities in bioaminergic neurotransmitters (noradrenaline, serotonin and dopamine) have been associated with the core clinical symptoms of FM and modulators of these systems have gained interest are potential treatments [8]. Cyclobenzaprine (flexeril, Amrix) is a tricyclic antidepressant with muscle relaxant properties that exhibits noradrenaline and serotonin reuptake inhibition. "
    [Show abstract] [Hide abstract] ABSTRACT: Introduction: Fibromyalgia (FM) is a common, complex chronic widespread pain condition is characterized by fatigue, sleep disturbance and cognitive dysfunction. Treatment of FM is difficult, requiring both pharmacological and non-pharmacological approaches, with an empiric approach to drug therapy focused toward individual symptoms, particularly pain. The effectiveness of current medications is limited with many patients discontinuing use. Areas covered: A systemic database search has identified 26 molecular entities as potential emerging drug therapies. Advances in the understanding of the pathophysiology of FM provides clues to targets for new medications. Investigation of bioamine modulation and  ligands and novel targets such as dopamine receptors, NMDA receptors, cannabinoid receptors, melatonin receptors and potassium channels has identified potential drug therapies. Expert opinion: Modest improvement of health status in patients with FM has been observed with drugs targeting a diverse range of molecular mechanisms. No single drug, however, offered substantial efficacy against all the symptoms characteristic of FM. Identification of new and improved therapies for FM needs to address the heterogeneity of the condition, which suggests existence of patient subgroups, the relationship of central and peripheral aspects of the pathophysiology and a requirement of combination therapy with drugs targeting multiple molecular mechanisms.
    Full-text · Article · Jun 2016
    • "Fibromyalgia is a complex painful syndrome, accompanied by a series of psychological and behavioral alterations (Busse et al., 2013), and characterized by chronic musculoskeletal pain (Wolfe et al., 2010). The hallmark symptom is chronic widespread pain, but patients also present fatigue, depression, cognitive dysfunctions , and sleep disturbances (Ceko et al., 2012; Wolfe et al., 2010). Many of these symptoms are also reported in patients with rheumatoid arthritis (Ryan, 2014). "
    [Show abstract] [Hide abstract] ABSTRACT: Omega-3 polyunsaturated fatty acids are essential for health and are known to possess anti-inflammatory properties, improving cardiovascular health as well as benefiting inflammatory diseases. Indeed, dietary supplementation with omega-3 polyunsaturated fatty acids has proved efficacious in reducing joint pain, morning stiffness and nonsteroidal anti-inflammatory drugs usage in rheumatoid arthritis patients. However, the mechanisms by which omega-3 polyunsaturated fatty acids exert their beneficial effects have not been fully explored. Seminal discoveries by Serhan and colleagues have unveiled a novel class of bioactive lipid mediators that are enzymatically biosynthesized in vivo from omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), termed resolvins, protectins and maresins. These bioactive pro-resolving lipid mediators provide further rationale for the beneficial effects of fish-oil enriched diets. These endogenous lipid mediators are spatiotemporally biosynthesized to actively regulate resolution by acting on specific G protein-coupled receptors (GPCRs) to initiate anti-inflammatory and pro-resolving signals that terminate inflammation. In this review, we will discuss the mechanism of actions of these molecules, including their analgesic and bone-sparing properties making them ideal therapeutic agonists for the treatment of inflammatory diseases such as rheumatoid arthritis. Copyright © 2015. Published by Elsevier B.V.
    Full-text · Article · Jul 2015
    • "Fibromyalgia syndrome (FMS) is a chronic medical condition associated with an amplification of pain signals in the central nervous system and decreased ability of the nervous system to inhibit concomitant pain responses [1,2] . In Europe, FMS has been estimated to affect approximately 4.7% of the general population, [3] with a high prevalence in females (female: male ratio of 9–10:1)456. "
    [Show abstract] [Hide abstract] ABSTRACT: Background: Previous qualitative research has revealed that people with fibromyalgia use daytime napping as a coping strategy for managing symptoms against clinical advice. Yet there is no evidence to suggest whether daytime napping is beneficial or detrimental for people with fibromyalgia. The purpose of this study is to explore how people use daytime naps and to determine the links between daytime napping and symptom severity in fibromyalgia syndrome. Methods: A community based sample of 1044 adults who had been diagnosed with fibromyalgia syndrome by a clinician completed an online questionnaire. Associations between napping behavior, sleep quality and fibromyalgia symptoms were explored using Spearman correlations, with possible predictors of napping behaviour entered into a logistic regression model. Differences between participants who napped on a daily basis and those who napped less regularly, as well as nap duration were explored. Results: Daytime napping was significantly associated with increased pain, depression, anxiety, fatigue, memory difficulties and sleep problems. Sleep problems and fatigue explained the greatest amount of variance in napping behaviour, p<0.010. Those who engaged in daytime naps for >30 minutes had higher memory difficulties (t=-3.45) and levels of depression (t = -2.50) than those who napped for shorter periods (<30mins) (p<0.010). Conclusions: Frequent use and longer duration of daytime napping was linked with greater symptom severity in people with fibromyalgia. Given the common use of daytime napping in people with fibromyalgia evidence based guidelines on the use of daytime napping in people with chronic pain are urgently needed.
    Full-text · Article · Jan 2015
Show more

  • undefined · undefined
  • undefined · undefined
  • undefined · undefined